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CASE PRESENTATION
A 48-year-old woman was admitted to our dialysis
center for hemodialysis treatments. She had been on
hemodialysis for 2 years at another facility, with end-stage
renal disease believed to be due to diabetes mellitus.
The past medical history was also remarkable for
atherosclerotic vascular disease with coronary angioplasty
and stenting performed the previous year. In addition, the
patient had hypothyroidism, hypertension, and peripheral
neuropathy. Medications included oral administration of
losartan, metoprolol, aspirin, and ferrous sulfate. Insulin
was self-administered and the dialysis facility treated with
intravenous epoetin alfa and paricalcitol. There was no
history of heavy alcohol consumption, smoking, or drug
use. Review of systems was notable for occasional
dyspnea, particularly with ambulation, fatigue and
daytime sleepiness, constipation, and intermittent pain in
both feet. Physical exam revealed a slightly obese woman
with blood pressure 148/71 mm Hg, pulse 68, normal
head, ears, eyes, nose, throat, and neck, lungs clear, heart
with regular rhythm and no extra sounds, abdomen soft
with normal bowel sounds, rectal exam was deferred,
extremities had trace peripheral edema, and pulses were
marginally diminished.
A major focus of the patient’s dialysis evaluation was
on her anemia treatment. She had been persistently
hyporesponsive to epoetin, with hemoglobin rarely
above 11 g/dl (target range 11–12 g/dl) (Table 1); most
measurements in the previous year had been between
9.5 and 10.5 g/dl. The weekly epoetin alfa dose had
progressively been increased; most recently, it was
54 000 U. Iron testing had consistently indicated moderate
to severe iron deficiency. The most recent test had been
performed 5–6 weeks earlier, transferrin saturation was
6.2% (target 420%), serum ferritin was 38 ng/ml (target
4100 ng/ml), and reticulocyte hemoglobin content was
26.2 pg (target 429 pg). Other potential causes of epoetin
alfa resistance had been studied, C-reactive protein (CRP)
was normal, parathyroid hormone (PTH) levels had varied,
and were never severely elevated. There was no obvious
infection or inflammation present, serum levels of folic
acid and vitamin B12 were normal, and no evidence of
hemolysis was found.
The patient’s iron deficiency had been treated in the
past with intravenous iron dextran. However, during an
administration 2 years prior she experienced severe back
pain and hypotension and had a sensation of choking.
Systolic blood pressure fell by approximately 55 mm Hg,
and resuscitative treatments were administered. The
patient was hospitalized briefly, but no long-term
disability resulted. Because of persistent iron deficiency,
the patient’s physicians decided to reattempt intravenous
iron treatment 4 months later. However, on the first
administration of 100 mg iron sucrose, systolic blood
pressure fell from 144 to 95 mm Hg over 30 min and the
patient noted the presence of a sensation of unpleasant
warmth and flushing. The dialysis treatment was
continued and symptoms resolved. It was decided that the
patient was likely allergic to all intravenous iron, and that
treatment with oral iron should be used instead. Ferrous
sulfate, 325 mg, was prescribed to be taken thrice daily.
The most recent laboratory tests were notable for
hemoglobin of 9.1 g/dl while treated with 18 000 U of
epoetin alfa intravenously thrice weekly. Fatigue and
dyspnea remained persistent symptoms. All readily
definable causes for the patient’s resistant anemia had
been explored and excluded, except for iron deficiency.
An extensive evaluation for occult bleeding as a source of
iron deficiency yielded no diagnosis. Consequently, the
clinicians were faced with difficult decisions as to the
further management of her iron deficiency anemia.
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DISCUSSION
Iron deficiency occurs frequently in hemodialysis patients.
The primary reason is excessive blood loss related to
retention in dialysis lines and filters, blood testing, and
surgical and accidental bleeding.1 In normal adults, less than
1–2 mg of iron is lost from the body per day, a fraction of the
body’s iron stores. In contrast, hemodialysis patients may lose
3–10 mg/day. Furthermore, during recombinant human
erythropoietin therapy iron demand increases in parallel
with accelerated erythropoiesis.1 As a result of reduced iron
supply and increased demand, the majority of hemodialysis
patients require treatment with intravenous iron.
The nephrologist caring for the patient considered a
number of therapeutic options for refractory anemia owing
to iron deficiency in a patient with hypersensitivity to
intravenous iron treatment. The therapeutic goals would be
to improve the hemoglobin level and reduce symptoms
referable to anemia. Four options were weighed (1)
continued progressive increase in epoetin dose, (2) transfu-
sion of erythrocytes, (3) intensified oral iron treatment, and
(4) challenge with the only form of intravenous iron that she
had not been previously treated with, sodium ferric
gluconate.
Progressive increase in epoetin dosing would be a
potentially useful, if somewhat inelegant approach to
refractory anemia owing to severe iron deficiency. The
patient was already receiving 54 000 U of epoetin alfa weekly,
a very high dose. Whether further increases in dose in the
setting of severe iron deficiency would lead to an improved
hemoglobin level is unclear. It is certainly an expensive
approach; the weekly cost at 54 000 U was probably already
over $600. In this case, the clinicians did decide to increase
the epoetin dose, but a 22% increment led to only a small and
transient increase in hemoglobin level.
A decision was made to attempt intensified oral iron
therapy. Previous studies, including three randomized
controlled trials have not demonstrated efficacy for oral iron
treatment in hemodialysis patients.2–4 However, like many
studies, these reports provided little data as to response
heterogeneity. Therefore, the possibility could not be
excluded that a small subgroup of patients might exist who
could benefit from treatment. With this reasoning, a trial of
closely monitored oral iron therapy was initiated. The patient
was given a 3-month course of oral iron with supplemental
ascorbic acid to improve iron absorption, with careful
attention to education and compliance. Ferrous sulfate was
prescribed, 325 mg four times daily. Unfortunately, it did not
result in improvement in iron indices or hemoglobin level.
Whether to challenge with intravenous sodium ferric
gluconate (or rechallenge with either of the two iron agents
previously used) was considered. Because of the previous
hypotensive hypersensitivity reactions, the decision hinged
on balancing the potential benefit of improved hemoglobin
and a reduction in fatigue and dyspnea against the risk of
another hypersensitivity reaction. In the United States, three
forms of intravenous iron are available, iron dextran, sodium
ferric gluconate, and iron sucrose. While any of these drugs
can cause immediate hypersensitivity, the reactions have been
most extensively reported and studied with iron dextran.
Iron dextran is composed of a dense core of iron surrounded
by dextran polymers of various size and branch structure.
The dextran component’s first clinical use was as an injectable
colloid solution for expansion of intravascular volume. While
clinically effective, severe anaphylactic reactions were occa-
sionally noted.5 With the inclusion of dextran in the iron
dextran compound, anaphylactic reactions continued to be
observed.
The etiology of intravenous iron-associated hypersensiti-
vity is incompletely understood. Two pathogenic pathways
appear to play a role, with the relative contribution varying in
different patients and with different intravenous iron drugs.
The first is an anaphylactoid-type reaction, with mast cell
release of histamine and other mediators. This process has
been difficult to document as histamine release tends to be
transient, short-lived, and difficult to measure. In contrast, a
more stable molecule released from mast cells, tryptase, can
be measured in serum and is a useful marker of recent
anaphylaxis.6 In one report, two cases of apparent intrave-
nous iron allergy were confirmed as mast cell mediated by a
doubling of serum tryptase levels.7
A second mechanism for intravenous iron-associated
hypersensitivity is increased vascular reactivity owing to the
release of free, unbound iron into the bloodstream. After
intravenous injection of iron, an ideal iron drug would tightly
bind iron, carrying it directly to cells of the reticuloendo-
thelial system for processing. In reality, iron drugs tend to be
somewhat ‘leaky’ with some of their iron load being released
immediately into the circulation.8,9 If there are adequate
amounts of unbound transferrin in circulation, then the
released iron is quickly buffered. Occasionally, however, the
amount of transferrin may be insufficient, and the excess iron
circulates as bioactive, free labile iron.9–11 In this state, iron
increases oxidative stress, and may cause hypotension and
other typical symptoms of hypersensitivity.
A dichotomous view of intravenous iron hypersensitivity
is that iron dextran reactions are mast cell mediated, owing to
Table 1 |
Date
Hemoglobin
(g/dl)
Erythropoietin
dose (u/w)
Serum ferritin
(mg/dl)
Transferrin
saturation
(%)
11/03 10.3 36 000
12/03 11.1 36 000 66 10.2
1/04 10.2 42 000
2/04 9.9 42 000
3/04 9.4 48 000 50 8.5
4/04 10 48 000
5/04 10.5 48 000
6/04 10.1 48 000 21 14.7
7/04 9.9 48 000
8/04 9.6 48 000
9/04 10.2 54 000 38 6.2
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allergy to dextran, whereas non-dextran iron reactions are
caused by free labile iron. The argument for iron dextran is
driven by the large number of early reports of dextran-
associated anaphylaxis.5 In fact, the observation that the rate
of hypersensitivity is high both for dextran colloid and iron
dextran suggests that the common component, dextran,
might be the antigenic link. However, if allergy to dextran
was the only etiologic factor, then hypersensitivity should
not occur with non-dextran forms of intravenous iron.
This is not the case, reactions do occur with the non-dextran
iron drugs, but they are generally less frequent and of a
milder intensity than with iron dextran. However, the similar
clinical manifestations (hypotension, flushing) and the
existence of at least occasional cross-reactivity between iron
dextran and non-dextran irons suggest that there is some
intertwining of causal pathways. A more complete under-
standing of these processes could serve as a foundation for
design of iron drugs that are even safer than the current
generation of agents.
Most studies of hypersensitivity reactions with intra-
venous iron drugs have used data derived from chart or
database review. This methodology is probably far from
optimal for determining the actual rate of reactions or for
comparisons between different iron drugs. The most
important limiting factor is that symptoms of iron
hypersensitivity reactions overlap greatly with intradialytic
symptoms that occur frequently during hemodialysis treat-
ments. This makes retrospective determination of causality
next to impossible. Database reviews are further limited by
the infrequency of reactions and substantial and inconsistent
under reporting. An ideal study would involve direct
observation of patients after injection with iron. One
published study, authored by Michael et al., included over
2500 hemodialysis patients, with direct, blinded, observation,
comparing reaction rates between sodium ferric gluconate
and placebo. One severe reaction (0.04%) with sodium ferric
gluconate was observed, a rate not statistically greater than
that for placebo.12 Other studies have relied on review of
patient charts or analyses of databases. Fishbane et al.13 and
Hamstra et al.14 found the rate of severe reaction with iron
dextran to be 0.6–0.7%. Walters and Van Wyck15 studied the
database of a large dialysis provider to identify severe
episodes of iron–dextran-induced anaphylaxis. They found
seven events out of 48 509 patients treated, all occurring with
the first dose of drug. Bailie et al.16 used the US Food and
Drug Administration’s Freedom of Information (FOI)
surveillance database to estimate rates of severe reactions
with iron drugs. The rate of reactions was found to be higher
with iron dextran than the non-dextran forms of iron,
although non-dextran irons did have rare severe reactions
associated with their use. Chertow et al.17 used similar
methodology, and found the rate of life-threatening reactions
to be less than 1 per million for non-dextran iron drugs and
3.3–11.3 per million for iron dextrans. The low rate of
reactions reported in this and other database reviews,
compared to the almost thousand fold greater incidence
with chart reviews, undoubtedly reflects the lack of sensitivity
of indirect data sources.
The patient in this report had previously experienced
hypersensitivity reactions with iron dextran and iron sucrose.
In deciding on whether to treat this patient with yet another
form of intravenous iron, knowledge about cross-reactivity of
hypersensitivity between the different iron drugs is critical. In
the study noted above by Michael et al. 143 of enrolled
subjects had a previous history of iron dextran allergy. These
patients received single, blinded doses of sodium ferric
gluconate and placebo. Treatment with sodium ferric
gluconate resulted in three suspected allergic reactions
(2.1%) compared to one (0.7%) with placebo. Patients with
history of iron dextran allergy had a seven fold increased rate
of reactions (all types, not just suspected allergy) to both
sodium ferric gluconate and placebo.18 These results indicate
a relatively low rate of cross-reactivity between iron dextran
and sodium ferric gluconate, and a degree of idiosyncrasy
that defies easy explanation. It is unclear why even placebo
exposure resulted in such a high rate of reactions in patients
previously sensitive to iron dextran. Cross-reactivity has also
been studied with iron sucrose. Van Wyck et al.19 studied iron
sucrose in 23 patients with previous reactions to iron
dextran, and found no serious reactions.
It could reasonably be concluded that non-dextran iron
drugs can be administered safely to most patients previously
sensitive to iron dextran, particularly when the reaction was
not severe. However, when a patient has experienced a severe
reaction with iron dextran, rechallenge with iron sucrose or
sodium ferric gluconate must be undertaken with particular
care. The likelihood of a reaction may be low, but the
potential severity of a reaction mandates that the expected
benefits must be substantial and clearly defined. In the case
under Discussion, the direct benefit to the patient would be
amelioration of the fatigue and dyspnea that she had
experienced. These symptoms had restricted the patient’s
activities, and degraded her quality of life. Therefore,
assuming a certain amount of treatment-associated risk
might have been acceptable.
One last option to consider before intravenous iron
treatment was that of blood transfusion. Blood transfusion
would effectively increase hemoglobin level and supply some
iron, but with minor risks for immune activation and
infection. Each ml of packed red cells contains 1 mg of iron,
in a typical unit approximately 180 mg of iron would be
supplied.
FOLLOW-UP
The nephrologist discussed the relative merits and risks of
transfusion and intravenous iron with the patient. A decision
was jointly made to treat with blood transfusions as needed
to maintain hemoglobin 411 g/dl. It was agreed that if the
transfusion requirements were persistent, that rechallenge
with intravenous iron would be reconsidered. The patient
received two units of packed red cells at this point, and was
transfused twice more in the ensuing 7 months (6 U total).
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Most hemoglobin measures were greater than 10.5 g/dl, and
the patient noted a significant reduction in fatigue and
dyspnea. Interestingly, in the subsequent 5 months, no
transfusions were required.
In conclusion, this case was notable for highlighting
several clinical decision points that may arise during epoetin
therapy. Treatment hyporesponse requires an evaluation for a
number of potential causes that can degrade responsiveness,
rather than continually increasing the epoetin dose. In this
case, while the cause of diminished response was a common
one, iron deficiency, the treatment options were limited by
sensitivity to intravenous iron. As in any area of medicine,
when the remaining treatment options are less than optimal,
shared decision-making yields the greatest understanding
and outcomes. The decision to rely on blood transfusion to
supplement epoetin treatment was something of a throwback
to the pre-erythropoietin era. While certainly not optimal,
the results in this case were satisfactory.
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